InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

InflaRx N.V.NASDAQ: IFRX

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -€0.08, compared with -€0.13 a year earlier. Trailing-twelve-month EPS (Basic) was -€0.61.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 4 analysts of -€0.21 (+68.4%) for the fiscal year ending Dec 2026, a step up from the +15.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€0.08+43.9% QoQ
Last fiscal yearDec 2025
-€0.66+15.4% YoY
LTMMar 2026
-€0.61+18.5% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.5%+72.3%+32.7 pp
1 year+15.4%+68.4%+53.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

EUR · from the income statement

Latest · FY2025
(0.66) EUR
Year-over-year change
+15.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +18.5% is the 3rd highest of 9, against a peer median of -13.2%.
IFRX Competitors
EPS (Basic) for IFRX and competitors
Company Period LTM YoY 3-year CAGR
CNTXContext Therapeutics Inc.LTM Mar 2026-$0.42 USD-15.1%—
IFRXInflaRx N.V.LTM Mar 2026-€0.61 EUR+18.5%—
STTKShattuck Labs, Inc.LTM Mar 2026-$0.63 USD+54.7%—
ATYRaTyr Pharma, Inc.LTM Mar 2026-$0.73 USD+9.9%—
CNTBConnect Biopharma Holdings LimitedFY2025-$1 USD-257.1%—
KLRSKalaris Therapeutics IncLTM Mar 2026-$2.15 USD+85.6%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$3.55 USD-11.3%—
IMAImageneBio IncLTM Mar 2026-$4.64 USD-439.2%—
STROSutro Biopharma, Inc.LTM Mar 2026-$307.72 USD-936.1%—
Peer median (excluding IFRX) —-13.2%—

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0063.09K165.79K29.33K
Cost of Revenue00532.26K3.32M7.27M
Gross Profit00(469.17K)(3.15M)(7.24M)
Gross Margin——-743.7%-1900.8%-24677.9%
Research & Development35.7M37.53M41.02M35.36M25.72M
Selling, General & Admin11.43M14.34M16.12M19.33M17.56M
Operating Expenses47.63M32.24M44.13M49.75M41.02M
Depreciation & Amortization669.43K596.6K567.78K485.11K419.48K
EBITDA(44.94M)(28.84M)(42.06M)(45.55M)(45.16M)
EBITDA Margin——-66674.3%-27476.7%-153976.3%
Operating Income(47.63M)(32.24M)(44.59M)(52.91M)(48.26M)
Operating Margin——-70685.6%-31911.4%-164525.5%
Interest Income109.39K608.68K3.8M3.2M1.77M
Interest Expense24.77K45.25K35.63K20.66K37.69K
Other Income / Expenses2M2.75M1.93M6.85M2.64M
Income Before Tax(45.63M)(29.48M)(42.67M)(46.06M)(45.62M)
Pre-Tax Margin——-67630.7%-27781.8%-155540.2%
Income Tax Expense0005.22K12.28K
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(45.63M)
Net Margin——-67630.7%-27785.0%-155582.1%
EPS (Basic)(1.10)(0.61)(0.78)(0.78)(0.66)
EPS (Diluted)(1.10)(0.61)(0.78)(0.78)(0.66)
Weighted Avg Shares41.63M44.21M54.94M58.92M67.29M
Weighted Avg Shares (Diluted)41.63M44.21M54.94M58.92M67.29M

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.